VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Navn VRTXON

Rang No.3637

Markedscap $0.00

Fuldt udvandet markedsværdi $0.00

Markedsandel %

Handelsvolumen/markedsværdi (24H) 18,680,955.51%

Cirkulationsforsyning 3.84400459

Max Udbud 0

Samlet Udbud 3.84400459

Cirkulationshastighed %

Udstedelsesdato --

Den pris, som aktivet først blev udstedt til --

Alle tiders høj 466.35223147502205, 2026-03-26

Laveste pris 414.92035330237934, 2026-05-05

Offentlig blockchain VRTXON

Indledning Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektor

Social Media

• Twitter

• Officiel hjemmeside
• Bloker Explorer

Fondstrømsanalyse

etfindex:mc_etfindex_source Ansvarsfraskrivelse: Data leveret af cmc og bør ikke betragtes som investeringsrådgivning.